Visit Website for Healthcare Professionals
See other indications for POMALYST:
This site is intended for US audiences only.
Explore relapsed multiple myeloma, from the definition of relapse to support that may help you on your journey.
Discover what relapsed myeloma is.
Learn how relapsed multiple myeloma can affect your loved one and how you can care for them—and yourself—appropriately.
Learn about My Momentum—a new program for people who are taking POMALYST for relapsed multiple myeloma or for people who want more information about POMALYST.
Discover POMALYST, an oral medicine used to treat people with relapsed multiple myeloma.
Discover how to take POMALYST, and view the dosing schedule
Learn more about FDA-approved therapy combinations, including POMALYST, to treat multiple myeloma.
Learn how to enroll in the POMALYST REMS program for multiple myeloma.
Learn about the possible side effects of POMALYST. See full Prescribing Information and Boxed WARNINGS.
Learn about the serious side effects of POMALYST.
Discover some of the most common side effects of POMALYST.
Learn about the resources available to you as a patient taking POMALYST® (pomalidomide) for relapsed multiple myeloma.
Find answers to frequently asked question about relapsed multiple myeloma.
Find out about organizations and resources that can help you better understand relapsed multiple myeloma.
Find relapsed multiple myeloma treatment resources available to share or download.
POMALYST is a prescription medicine, taken along with the medicine dexamethasone, used to treat adults with multiple myeloma who have previously received at least 2 medicines to treat multiple myeloma, including a proteasome inhibitor and lenalidomide, and whose disease has become worse during treatment or within 60 days of finishing the last treatment. It is not known if POMALYST is safe and effective in children.
The REMS Companion App
Easily access the POMALYST REMS® program.
It’s time for a different treatment. Ask your doctor about oral POMALYST with convenient, once-daily dosing.‡
*Patients must have also received a proteasome inhibitor (PI).
†Please see full Prescribing Information, including Boxed WARNINGS, for REVLIMID.
‡POMALYST is taken in combination with dexamethasone on days 1-21 of a 28-day cycle.
Not the actual capsule size.
“When I relapsed, my doctor suggested we change to a POMALYST-containing regimen.”*
*After receiving lenalidomide and a proteasome inhibitor.
Jen is currently taking a POMALYST® (pomalidomide) containing regimen. Jen was compensated by BMS for her participation.
Explore approved triplet combination therapies containing POMALYST® (pomalidomide) + dexamethasone in RRMM
RRMM, relapsed/refractory multiple myeloma.
Laurie is no longer taking POMALYST.
Make the next visit to your doctor’s office more informative
Get help finding questions to ask your doctor.
Michele is a caregiver for someone currently taking POMALYST.
Download the REMS Companion App
Use the app to complete your monthly REMS survey on your smartphone.
Depending on your insurance situation, there are programs and organizations that may help pay for POMALYST.
Access tools to help you learn about multiple myeloma.
This website is best viewed
using the horizontal display
on your tablet device.
This website is best viewed
using the vertical display
on your mobile device.